The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Aptamers as targeted therapeutics: current potential and challenges
Open accessAbstract
Nucleic acid aptamers, often termed 'chemical antibodies', are functionally comparable to traditional antibodies, but offer several advantages, including their relatively small physical size, flexible structure, quick chemical production, versatile chemical modification, high stability and lack of immunogenicity. In addition, many aptamers are internalized upon binding to cellular receptors, making them useful targeted delivery agents for small interfering RNAs (siRNAs), microRNAs and conventional drugs. However, several crucial factors have delayed the clinical translation of therapeutic aptamers, such as their inherent physicochemical characteristics and lack of safety data. This Review discusses these challenges, highlighting recent clinical developments and technological advances that have revived the impetus for this promising class of therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase
Cerchia, L., Ducongé, F., Pestourie, C., Boulay, J., Aissouni, Y., Gombert, K., Tavitian, B., de Franciscis, V., & Libri, D. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030123 · Cited by 246
RetractedTuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Selection of single-stranded DNA molecules that bind and inhibit human thrombin
Bock, L. C., Griffin, L. C., Latham, J. A., Vermaas, E. H., & Toole, J. J. (1992) · Nature · doi:10.1038/355564a0 · Cited by 2,469
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544
Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA
Robertson, D. L., & Joyce, G. F. (1990) · Nature · doi:10.1038/344467a0 · Cited by 1,331
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2015) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,286
Burns, J. M., Summers, B. C., Wang, Y., Melikian, A., Berahovich, R., Miao, Z., Penfold, M. E. T., Sunshine, M. J., Littman, D. R., Kuo, C. J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052144 · Cited by 1,263
High-Resolution Molecular Discrimination by RNA
Jenison, R. D., Gill, S. C., Pardi, A., & Polisky, B. (1994) · Science · doi:10.1126/science.7510417 · Cited by 1,188
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Ghasemi Falavarjani, K., & Nguyen, Q. D. (2013) · Eye · doi:10.1038/eye.2013.107 · Cited by 982
Aptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Ellington, A. D., & Szostak, J. W. (1992) · Nature · doi:10.1038/355850a0 · Cited by 856
Axel, D. I., Kunert, W., Göggelmann, C., Oberhoff, M., Herdeg, C., Küttner, A., Wild, D. H., Brehm, B. R., Riessen, R., Köveker, G., et al. (1997) · Circulation · doi:10.1161/01.cir.96.2.636 · Cited by 784
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
The emerging field of RNA nanotechnology
Guo, P. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2010.231 · Cited by 718
Current approaches in SELEX: An update to aptamer selection technology
Darmostuk, M., Rimpelova, S., Gbelcova, H., & Ruml, T. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.02.008 · Cited by 702
An Aptamer–Doxorubicin Physical Conjugate as a Novel Targeted Drug‐Delivery Platform
Bagalkot, V., Farokhzad, O. C., Langer, R., & Jon, S. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602251 · Cited by 613
Sassanfar, M., & Szostak, J. W. (1993) · Nature · doi:10.1038/364550a0 · Cited by 593
The Chemical Biology of Aptamers
Mayer, G. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200804643 · Cited by 592
Immunogenicity of therapeutic proteins: Influence of aggregation
Ratanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.821564 · Cited by 589
Dassie, J. P., Liu, X.-Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 589
Rescuing the function of mutant p53
Bullock, A. N., & Fersht, A. R. (2001) · Nature Reviews Cancer · doi:10.1038/35094077 · Cited by 568
Bias and artifacts in multitemplate polymerase chain reactions (PCR)
Kanagawa, T. (2003) · Journal of Bioscience and Bioengineering · doi:10.1016/s1389-1723(03)90130-7 · Cited by 566
RNA aptamers as reversible antagonists of coagulation factor IXa
Rusconi, C. P., Scardino, E., Layzer, J., Pitoc, G. A., Ortel, T. L., Monroe, D., & Sullenger, B. A. (2002) · Nature · doi:10.1038/nature00963 · Cited by 512
The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer Cells
Soundararajan, S., Chen, W., Spicer, E. K., Courtenay-Luck, N., & Fernandes, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5723 · Cited by 512
Selection of Aptamers for Molecular Recognition and Characterization of Cancer Cells
Tang, Z., Shangguan, D., Wang, K., Shi, H., Sefah, K., Mallikratchy, P., Chen, H. W., Li, Y., & Tan, W. (2007) · Analytical Chemistry · doi:10.1021/ac070189y · Cited by 479
Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 469
Medicine, N. L. O. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280801989377 · Cited by 468
Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes
Pieken, W. A., Olsen, D. B., Benseler, F., Aurup, H., & Eckstein, F. (1991) · Science · doi:10.1126/science.1857967 · Cited by 463
Aptamer mediated siRNA delivery
Chu, T. C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl388 · Cited by 446
THE EYETECH STUDY GROUP (2002) · Retina · doi:10.1097/00006982-200204000-00002 · Cited by 415
Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding
Bates, P. J., Kahlon, J. B., Thomas, S. D., Trent, J. O., & Miller, D. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.26369 · Cited by 407
Inhibitory DNA Ligands to Platelet-Derived Growth Factor B-Chain
Green, L. S., Jellinek, D., Jenison, R., Östman, A., Heldin, C.-H., & Janjic, N. (1996) · Biochemistry · doi:10.1021/bi961544+ · Cited by 390
Tumor targeting by an aptamer.
Hicke, B. J., Stephens, A. W., Gould, T. A., Chang, Y.-F., Lynott, C. K., Heil, J., Borkowski, S., Hilger, C. S., Cook, G., Warren, S., et al. (2006) · PubMed · Cited by 384
Reyes-Reyes, E. M., Teng, Y., & Bates, P. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0920 · Cited by 383
DiGiusto, D. L., Krishnan, A., Li, L., Li, H., Li, S., Rao, A., Mi, S., Yam, P., Stinson, S., Kalos, M., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000931 · Cited by 374
Self-citationModified deoxyoligonucleotides stable to exonuclease degradation in serum
Shaw, J.-P., Kent, K., Bird, J., Fishback, J., & Froehler, B. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.4.747 · Cited by 369
Geiger, A. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.6.1029 · Cited by 368
Liang, C., Guo, B., Wu, H., Shao, N., Li, D., Liu, J., Dang, L., Wang, C., Li, H., Li, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3791 · Cited by 354
Direct In Vitro Selection of a 2′-O-Methyl Aptamer to VEGF
Burmeister, P. E., Lewis, S. D., Silva, R. F., Preiss, J. R., Horwitz, L. R., Pendergrast, P. S., McCauley, T. G., Kurz, J. C., Epstein, D. M., Wilson, C., et al. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.10.017 · Cited by 347
Antidote-mediated control of an anticoagulant aptamer in vivo
Rusconi, C. P., Roberts, J. D., Pitoc, G. A., Nimjee, S. M., White, R. R., Quick, G., Scardino, E., Fay, W. P., & Sullenger, B. A. (2004) · Nature Biotechnology · doi:10.1038/nbt1023 · Cited by 339
Tenascin-C Aptamers Are Generated Using Tumor Cells and Purified Protein
Hicke, B. J., Marion, C., Chang, Y.-F., Gould, T., Lynott, C. K., Parma, D., Schmidt, P. G., & Warren, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104651200 · Cited by 324
Jo, N., Mailhos, C., Ju, M., Cheung, E., Bradley, J., Nishijima, K., Robinson, G. S., Adamis, A. P., & Shima, D. T. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050588 · Cited by 322
Expanding the Chemistry of DNA for in Vitro Selection
Vaught, J. D., Bock, C., Carter, J., Fitzwater, T., Otis, M., Schneider, D., Rolando, J., Waugh, S., Wilcox, S. K., & Eaton, B. E. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908035g · Cited by 313
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice
McNamara, J. O., Kolonias, D., Pastor, F., Mittler, R. S., Chen, L., Giangrande, P. H., Sullenger, B., & Gilboa, E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33365 · Cited by 310
Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 Therapy
Zhou, J., Li, H., Li, S., Zaia, J., & Rossi, J. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.92 · Cited by 301
Self-citationPharmacokinetics and Biodistribution of Novel Aptamer Compositions
Healy, J. M., Lewis, S. D., Kurz, M., Boomer, R. M., Thompson, K. M., Wilson, C., & McCauley, T. G. (2004) · Pharmaceutical Research · doi:10.1007/s11095-004-7676-4 · Cited by 298
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
Pastor, F., Kolonias, D., Giangrande, P. H., & Gilboa, E. (2010) · Nature · doi:10.1038/nature08999 · Cited by 294
Gilbert, J. C., DeFeo-Fraulini, T., Hutabarat, R. M., Horvath, C. J., Merlino, P. G., Marsh, H. N., Healy, J. M., BouFakhreddine, S., Holohan, T. V., & Schaub, R. G. (2007) · Circulation · doi:10.1161/circulationaha.107.724864 · Cited by 286
Aptamer:Toxin Conjugates that Specifically Target Prostate Tumor Cells
Chu, T. C., Marks, J. W., Lavery, L. A., Faulkner, S., Rosenblum, M. G., Ellington, A. D., & Levy, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4583 · Cited by 284
SELEX with modified nucleotides
Keefe, A. D., & Cload, S. T. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.06.028 · Cited by 283
Ganson, N. J., Povsic, T. J., Sullenger, B. A., Alexander, J. H., Zelenkofske, S. L., Sailstad, J. M., Rusconi, C. P., & Hershfield, M. S. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.034 · Cited by 273
Shu, D., Li, H., Shu, Y., Xiong, G., Carson, W. E., Haque, F., Xu, R., & Guo, P. (2015) · ACS Nano · doi:10.1021/acsnano.5b02471 · Cited by 270
In vivo selection of tumor-targeting RNA motifs
Mi, J., Liu, Y., Rabbani, Z. N., Yang, Z., Urban, J. H., Sullenger, B. A., & Clary, B. M. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.277 · Cited by 269
The roles of nucleolin subcellular localization in cancer
Berger, C. M., Gaume, X., & Bouvet, P. (2015) · Biochimie · doi:10.1016/j.biochi.2015.03.023 · Cited by 267
Quantitative selection of DNA aptamers through microfluidic selection and high-throughput sequencing
Cho, M., Xiao, Y., Nie, J., Stewart, R., Csordas, A. T., Oh, S. S., Thomson, J. A., & Soh, H. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009331107 · Cited by 267
Zhou, J., Swiderski, P., Li, H., Zhang, J., Neff, C. P., Akkina, R., & Rossi, J. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp185 · Cited by 267
Self-citationOligonucleotides as Research, Diagnostic, and Therapeutic Agents
Gold, L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.23.13581 · Cited by 266
Aptamer Nanomedicine for Cancer Therapeutics: Barriers and Potential for Translation
Lao, Y.-H., Phua, K. K. L., & Leong, K. W. (2015) · ACS Nano · doi:10.1021/nn507494p · Cited by 259
Neff, C. P., Zhou, J., Remling, L., Kuruvilla, J., Zhang, J., Li, H., Smith, D. D., Swiderski, P., Rossi, J. J., & Akkina, R. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001581 · Cited by 259
Self-citationTherapeutic RNA aptamers in clinical trials
Sundaram, P., Kurniawan, H., Byrne, M. E., & Wower, J. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.10.014 · Cited by 259
Kohn, D. B., Bauer, G., Rice, C. R., Rothschild, J. C., Carbonaro, D. A., Valdez, P., Hao, Q.-L., Zhou, C., Bahner, I., Kearns, K., et al. (1999) · Blood · doi:10.1182/blood.v94.1.368.413a47_368_371 · Cited by 258
Hirao, I., Kimoto, M., Mitsui, T., Fujiwara, T., Kawai, R., Sato, A., Harada, Y., & Yokoyama, S. (2006) · Nature Methods · doi:10.1038/nmeth915 · Cited by 252
Cell‐Specific Internalization Study of an Aptamer from Whole Cell Selection
Xiao, Z., Shangguan, D., Cao, Z., Fang, X., & Tan, W. (2008) · Chemistry – A European Journal · doi:10.1002/chem.200701330 · Cited by 246
Stable RNA nanoparticles as potential new generation drugs for cancer therapy
Shu, Y., Pi, F., Sharma, A., Rajabi, M., Haque, F., Shu, D., Leggas, M., Evers, B. M., & Guo, P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.006 · Cited by 244
Hoellenriegel, J., Zboralski, D., Maasch, C., Rosin, N. Y., Wierda, W. G., Keating, M. J., Kruschinski, A., & Burger, J. A. (2014) · Blood · doi:10.1182/blood-2013-03-493924 · Cited by 242
Plasma Membrane Nucleolin Is a Receptor for the Anticancer Aptamer AS1411 in MV4-11 Leukemia Cells
Soundararajan, S., Wang, L., Sridharan, V., Chen, W., Courtenay-Luck, N., Jones, D., Spicer, E. K., & Fernandes, D. J. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.055947 · Cited by 240
Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy
Zhou, J., & Rossi, J. J. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.21 · Cited by 234
Self-citationNovel Approach to Specific Growth Factor Inhibition in Vivo
Floege, J., Ostendorf, T., Janssen, U., Burg, M., Radeke, H. H., Vargeese, C., Gill, S. C., Green, L. S., & Janjic, N. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65263-7 · Cited by 233
Capillary Electrophoresis-SELEX Selection of Aptamers with Affinity for HIV-1 Reverse Transcriptase
Mosing, R. K., Mendonsa, S. D., & Bowser, M. T. (2005) · Analytical Chemistry · doi:10.1021/ac050836q · Cited by 232
Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures
Mayer, G., Ahmed, M.-S. L., Dolf, A., Endl, E., Knolle, P. A., & Famulok, M. (2010) · Nature Protocols · doi:10.1038/nprot.2010.163 · Cited by 231
Dyke, C. K., Steinhubl, S. R., Kleiman, N. S., Cannon, R. O., Aberle, L. G., Lin, M., Myles, S. K., Melloni, C., Harrington, R. A., Alexander, J. H., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.668434 · Cited by 222
Single-molecule PCR using water-in-oil emulsion
Nakano, M., Komatsu, J., Matsuura, S.-I., Takashima, K., Katsura, S., & Mizuno, A. (2003) · Journal of Biotechnology · doi:10.1016/s0168-1656(03)00023-3 · Cited by 218
Targeting cancer cells with nucleic acid aptamers
Cerchia, L., & de Franciscis, V. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.07.005 · Cited by 218
Potent 2'-Amino-2'-deoxypyrimidine RNA Inhibitors of Basic Fibroblast Growth Factor
Jellinek, D., Green, L. S., Bell, C., Lynott, C. K., Gill, N., Vargeese, C., Kirschenheuter, G., McGee, D. P. C., & Abesinghe, P. (1995) · Biochemistry · doi:10.1021/bi00036a009 · Cited by 215
In vivo SELEX for Identification of Brain-penetrating Aptamers
Cheng, C., Chen, Y. H., Lennox, K. A., Behlke, M. A., & Davidson, B. L. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.59 · Cited by 214
Drolet, D. W., Nelson, J., Tucker, C. E., Zack, P. M., Nixon, K., Bolin, R., Judkins, M. B., Farmer, J. A., Wolf, J. L., Gill, S. C., et al. (2000) · Pharmaceutical Research · doi:10.1023/a:1007657109012 · Cited by 206
Embracing proteins: structural themes in aptamer–protein complexes
Gelinas, A. D., Davies, D. R., & Janjic, N. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.01.009 · Cited by 206
Henry, S. P., Giclas, P. C., Leeds, J., Pangburn, M., Auletta, C., Levin, A. A., & Kornbrust, D. J. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36667-4 · Cited by 204
Chen, C.-H. B., Chernis, G. A., Hoang, V. Q., & Landgraf, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1332660100 · Cited by 190
Spiegelmer Inhibition of CCL2/MCP-1 Ameliorates Lupus Nephritis in MRL-(Fas)lpr Mice
Kulkarni, O., Pawar, R. D., Purschke, W., Eulberg, D., Selve, N., Buchner, K., Ninichuk, V., Segerer, S., Vielhauer, V., Klussmann, S., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006121348 · Cited by 187
Assembling OX40 Aptamers on a Molecular Scaffold to Create a Receptor-Activating Aptamer
Dollins, C. M., Nair, S., Boczkowski, D., Lee, J., Layzer, J. M., Gilboa, E., & Sullenger, B. A. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.05.016 · Cited by 183
Modified RNA sequence pools for in vitro selection
Lin, Y., Qiu, Q., Gill, S. C., & Jayasena, S. D. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.24.5229 · Cited by 182
Liposome-Anchored Vascular Endothelial Growth Factor Aptamers
Willis, M. C., Collins, B., Zhang, T., Green, L. S., Sebesta, D. P., Bell, C., Kellogg, E., Gill, S. C., Magallanez, A., Knauer, S., et al. (1998) · Bioconjugate Chemistry · doi:10.1021/bc980002x · Cited by 181
Enrichment of Cell‐Targeting and Population‐Specific Aptamers by Fluorescence‐Activated Cell Sorting
Raddatz, M. L., Dolf, A., Endl, E., Knolle, P., Famulok, M., & Mayer, G. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200800216 · Cited by 178
Tucker, C. E., Chen, L.-S., Judkins, M. B., Farmer, J. A., Gill, S. C., & Drolet, D. W. (1999) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/s0378-4347(99)00285-6 · Cited by 176
CELL-SELEX: Novel Perspectives of Aptamer-Based Therapeutics
Guo, K.-T., Ziemer, G., Paul, A., & Wendel, H. P. (2008) · International Journal of Molecular Sciences · doi:10.3390/ijms9040668 · Cited by 169
Ozer, A., Pagano, J. M., & Lis, J. T. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.34 · Cited by 168
Lincoff, A. M., Mehran, R., Povsic, T. J., Zelenkofske, S. L., Huang, Z., Armstrong, P. W., Steg, P. G., Bode, C., Cohen, M. G., Buller, C. E. H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00515-2 · Cited by 167
Sayyed, S. G., Hägele, H., Kulkarni, O. P., Endlich, K., Segerer, S., Eulberg, D., Klussmann, S., & Anders, H.-J. (2009) · Diabetologia · doi:10.1007/s00125-009-1493-6 · Cited by 166
Mongélard, F., & Bouvet, P. (2010) · PubMed · Cited by 164
Huang, C.-J., Lin, H.-I., Shiesh, S., et al. (2009) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2009.12.029 · Cited by 159
Schwoebel, F., van Eijk, L. T., Zboralski, D., Sell, S., Buchner, K., Maasch, C., Purschke, W. G., Humphrey, M., Zöllner, S., Eulberg, D., et al. (2013) · Blood · doi:10.1182/blood-2012-09-456756 · Cited by 158
Duerschmied, D., Merhi, Y., Tanguay, J., Hutabarat, R. M., GILBERT, J., Wagner, D. D., Schaub, R. G., Diener, J. L., & Lagassé, H. A. D. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03459.x · Cited by 156
Ohuchi, S. P. (2012) · BioResearch open access · doi:10.1089/biores.2012.0253 · Cited by 152
Derivation of RNA aptamer inhibitors of human complement C5
Biesecker, G., Dihel, L., Enney, K., & Bendele, R. A. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00020-x · Cited by 152
The Crystal Structure of the Costimulatory OX40-OX40L Complex
Compaan, D. M., & Hymowitz, S. G. (2006) · Structure · doi:10.1016/j.str.2006.06.015 · Cited by 150
High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding.
Jellinek, D., Lynott, C. K., Rifkin, D. B., & Janjić, N. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11227 · Cited by 149
Liposome-Anchored Vascular Endothelial Growth Factor Aptamers
Willis, M. C., Collins, B. T., Zhang, T., Green, L. S., Sebesta, D. P., Bell, C. J., Kellogg, E. A., Gill, S. C., Magallanez, A., Knauer, S., et al. (1998) · Bioconjugate Chemistry · doi:10.1021/bc980200o · Cited by 146
Waters, E. K., Genga, R. M. J., Schwartz, M. C., Nelson, J. A., Schaub, R. G., Olson, K. A., Kurz, J. C., & McGinness, K. E. (2011) · Blood · doi:10.1182/blood-2010-10-311936 · Cited by 143
Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts
Ni, X., Zhang, Y., Ribas, J., Chowdhury, W. H., Castanares, M. A., Zhang, Z., Laiho, M., DeWeese, T. L., & Lupold, S. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45109 · Cited by 143
Pastor, F., Kolonias, D. S., McNamara, J. O., & Gilboa, E. (2011) · Molecular Therapy · doi:10.1038/mt.2011.145 · Cited by 136
Molecular Evolution of Functional Nucleic Acids with Chemical Modifications
Kuwahara, M., & Sugimoto, N. (2010) · Molecules · doi:10.3390/molecules15085423 · Cited by 136
Ninichuk, V., Clauß, S., Kulkarni, O. P., Schmid, H., Segerer, S., Radomska, E., Eulberg, D., Buchner, K., Selve, N., Klußmann, S., et al. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070601 · Cited by 135
Emulsion PCR: A High Efficient Way of PCR Amplification of Random DNA Libraries in Aptamer Selection
Shao, K., Ding, W., Wang, F., Li, H., Ma, D., & Wang, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024910 · Cited by 134
Musheev, M. U., & Krylov, S. N. (2005) · Analytica Chimica Acta · doi:10.1016/j.aca.2005.09.069 · Cited by 134
The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation
Chen, L., Rashid, F., Shah, A., Awan, H. M., Wu, M., Liu, A., Wang, J., Zhu, T., Luo, Z., & Shan, G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502159112 · Cited by 129
Selection of Smart Aptamers by Methods of Kinetic Capillary Electrophoresis
Drabovich, A. P., Berezovski, M. V., Okhonin, V., & Krylov, S. N. (2006) · Analytical Chemistry · doi:10.1021/ac060144h · Cited by 128
CD28 Aptamers as Powerful Immune Response Modulators
Pastor, F., Soldevilla, M. M., Villanueva, H., Kolonias, D. S., Inogés, S., de Cerio, A. L.-D., Kandzia, R., Klimyuk, V. I., Gleba, Y. Y., Gilboa, E., et al. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.26 · Cited by 126
Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery
Hoinka, J., Berezhnoy, A., Dao, P., Sauna, Z. E., Gilboa, E., & Przytycka, T. M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv308 · Cited by 125
Fit for the Eye: Aptamers in Ocular Disorders
Drolet, D. W., Green, L. S., Gold, L., & Janjić, N. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0573 · Cited by 124
Zhou, J., Neff, C. P., Swiderski, P. M., Li, H., Smith, D. D., Aboellail, T., Remling‐Mulder, L., Akkina, R., & Rossi, J. J. (2012) · Molecular Therapy · doi:10.1038/mt.2012.226 · Cited by 122
Self-citationThiel, W. H., Bair, T., Peek, A. S., Liu, X., Dassie, J. P., Stockdale, K. R., Behlke, M. A., Miller, F. J., & Giangrande, P. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043836 · Cited by 114
Povsic, T. J., Vavalle, J. P., Aberle, L. H., Kasprzak, J. D., Cohen, M. G., Mehran, R., Bode, C., Buller, C. E. H., Montalescot, G., Cornel, J. H., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs232 · Cited by 111
A nucleolar TAR decoy inhibitor of HIV-1 replication
Michienzi, A., Li, S. X., Zaia, J. A., & Rossi, J. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212229599 · Cited by 110
Self-citationThe potential of aptamers as anticoagulants
Nimjee, S. M., Rusconi, C. P., Harrington, R. A., & Sullenger, B. A. (2005) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2005.01.002 · Cited by 109
Methods for selection of aptamers to protein targets
Kulbachinskiy, A. V. (2007) · Biochemistry (Moscow) · doi:10.1134/s000629790713007x · Cited by 108
Choi, D. Y., Ortube, M. C., McCannel, C. A., Sarraf, D., Hubschman, J., McCannel, T. A., & Gorin, M. B. (2011) · Retina · doi:10.1097/iae.0b013e318217ffde · Cited by 107
Lee, C. H., Lee, S.-H., Kim, J. H., Noh, Y.-H., Noh, G., & Lee, S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.30 · Cited by 106
Oberthüer, D., Achenbach, J., Gabdulkhakov, A. G., Buchner, K., Maasch, C., Falke, S., Rehders, D., Klußmann, S., & Betzel, C. (2015) · Nature Communications · doi:10.1038/ncomms7923 · Cited by 104
Musumeci, D., & Montesarchio, D. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.011 · Cited by 103
Cohen, M. G., Purdy, D. A., Rossi, J. S., Grinfeld, L. R., Myles, S. K., Aberle, L. H., Greenbaum, A. B., Fry, E. T. A., Chan, M. Y., Tonkens, R. M., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.927756 · Cited by 100
Self-citationBlockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats
Liu, S.-C., Alomran, R., Chernikova, S. B., Lartey, F. M., Stafford, J. H., Jang, T., Merchant, M. J., Zboralski, D., Zöllner, S. K., Kruschinski, A., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not149 · Cited by 100
Pegaptanib: In Exudative Age-Related Macular Degeneration
Siddiqui, M. A. A., & Keating, G. M. (2005) · Drugs · doi:10.2165/00003495-200565110-00010 · Cited by 98
The molecular mechanisms of immunomodulation and tolerance induction to factor VIII
Waters, B., & Lillicrap, D. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03538.x · Cited by 97
A Unique Folate Hydrolase, Prostate-Specific Membrane Antigen (PSMA): A Target For Immunotherapy?
Tasch, J. E., Gong, M., Sadelain, M., & Heston, W. D. W. (2001) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v21.i1-3.160 · Cited by 92
Boyacıoğlu, O., Stuart, C. H., Kulik, G., & Gmeiner, W. H. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.37 · Cited by 92
Liu, Y., Kuan, C., Mi, J., Zhang, X., Clary, B. M., Bigner, D. D., & Sullenger, B. A. (2008) · Biological Chemistry · doi:10.1515/bc.2009.022 · Cited by 92
Toward third-generation aptamers: Spiegelmers and their therapeutic prospects.
Vater, A., & Klußmann, S. (2003) · PubMed · Cited by 91
Aptamer Selection by High-Throughput Sequencing and Informatic Analysis
Hoon, S. S., Zhou, B., Janda, K. D., Brenner, S., & Scolnick, J. A. (2011) · BioTechniques · doi:10.2144/000113786 · Cited by 89
Vascular Endothelial Cell Growth Factor-A
D'Amore, P. A. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070385 · Cited by 84
Levay, A. K., Brenneman, R., Hoinka, J., Sant, D., Cardone, M., Trinchieri, G., Przytycka, T. M., & Berezhnoy, A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv534 · Cited by 84
Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
Agrawal, S., Joshi, M., & Christoforidis, J. B. (2013) · Mediators of Inflammation · doi:10.1155/2013/943409 · Cited by 83
Soldevilla, M. M., Villanueva, H., Bendandi, M., Inogés, S., de Cerio, A. L.-D., & Pastor, F. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.020 · Cited by 79
Yufa, R., Krylova, S. M., Bruce, C., Bagg, E. A. L., Schofield, C. J., & Krylov, S. N. (2014) · Analytical Chemistry · doi:10.1021/ac5044187 · Cited by 79
Lü, P., Stephens, B. J., Bonin, K., Cubicciotti, R., & Guthold, M. (2007) · Microscopy Research and Technique · doi:10.1002/jemt.20421 · Cited by 76
Hi‐Fi SELEX: A high‐fidelity digital‐PCR based therapeutic aptamer discovery platform
Ouellet, E., Foley, J. H., Conway, E. M., & Haynes, C. A. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25581 · Cited by 76
Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors
Gilboa, E., McNamara, J. O., & Pastor, F. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2067 · Cited by 76
Aptamer-Based Therapeutics: New Approaches to Combat Human Viral Diseases
Shum, K., Zhou, J., & Rossi, J. P. (2013) · Pharmaceuticals · doi:10.3390/ph6121507 · Cited by 75
Self-citationCell-Specific Aptamers for Targeted Therapies
Cerchia, L., Giangrande, P. H., McNamara, J. O., & de Franciscis, V. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-557-2_5 · Cited by 73
DNA Aptamer Assembly as a Vascular Endothelial Growth Factor Receptor Agonist
Ramaswamy, V., Monsalve, A. G., Sautina, L., Segal, M. S., Dobson, J., & Allen, J. B. (2015) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0519 · Cited by 72
Yunn, N.-O., Koh, A., Han, S., Lim, J. H., Park, S., Lee, J., Kim, E., Jang, S. K., Berggren, P., & Ryu, S. H. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv767 · Cited by 71
A streamlined protocol for emulsion polymerase chain reaction and subsequent purification
Schütze, T., Rubelt, F., Repkow, J., Greiner, N., Erdmann, V. A., Lehrach, H., Konthur, Z., & Glökler, J. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.11.029 · Cited by 71
Synthesis and properties of oligodeoxyribonucleotide—polyethylene glycol conjugates
Jäschke, A., Fürste, J. P., Nordhoff, E., Hillenkamp, F., Cech, D., & Erdmann, V. A. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4810 · Cited by 69
Comparison of Different Strategies to Select Aptamers Against a Transmembrane Protein Target
Pestourie, C., Cerchia, L., Gombert, K., Aissouni, Y., Boulay, J., de Franciscis, V., Libri, D., Tavitian, B., & Ducongè, F. (2006) · Oligonucleotides · doi:10.1089/oli.2006.16.323 · Cited by 68
Pratico, E. D., Sullenger, B. A., & Nair, S. K. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0388 · Cited by 67
Kawa, M. P., Machalińska, A., Rogińska, D., & Machaliński, B. (2014) · Journal of Immunology Research · doi:10.1155/2014/483960 · Cited by 66
Nucleotide Bias Observed with a Short SELEX RNA Aptamer Library
Thiel, W. H., Bair, T., Wyatt Thiel, K., Dassie, J. P., Rockey, W. M., Howell, C. A., Liu, X. Y., Dupuy, A. J., Huang, L., Owczarzy, R., et al. (2011) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0288 · Cited by 66
Aptamers as radiopharmaceuticals for nuclear imaging and therapy
Gijs, M., Aerts, A., Impens, N. R. E. N., Baatout, S., & Luxen, A. (2015) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2015.09.005 · Cited by 65
A Hybrid DNA Aptamer–Dendrimer Nanomaterial for Targeted Cell Labeling
Zhou, J., Soontornworajit, B., Martin, J. T., Sullenger, B. A., Gilboa, E., & Wang, Y. (2009) · Macromolecular Bioscience · doi:10.1002/mabi.200900046 · Cited by 63
Self-citationSelective delivery of therapeutic single strand antimiRs by aptamer-based conjugates
Catuogno, S., Rienzo, A., Vito, A. D., Esposito, C. L., & de Franciscis, V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.276 · Cited by 62
Structural characterization of a 2′F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120
Sayer, N. M., Ibrahim, J., Turner, K., Tahiri‐Alaoui, A., & James, W. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00308-x · Cited by 62
VEGF inhibitors for the treatment of neovascular age-related macular degeneration
Barakat, M., & Kaiser, P. K. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902855316 · Cited by 62
In vitro selection of BNA (LNA) aptamers
Kuwahara, M., & Obika, S. (2013) · Artificial DNA PNA & XNA · doi:10.4161/adna.25786 · Cited by 62
Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration
Mousa, S. A., & Mousa, S. S. (2010) · BioDrugs · doi:10.2165/11318550-000000000-00000 · Cited by 61
Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications
Farman, C. A., & Kornbrust, D. J. (2003) · Toxicologic Pathology · doi:10.1080/01926230390174995 · Cited by 61
Veedu, R. N., & Wengel, J. (2009) · Molecular BioSystems · doi:10.1039/b905513b · Cited by 60
Lee, Y.-J., Urban, J. H., Xu, L., Sullenger, B. A., & Lee, J. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0575 · Cited by 60
Gorczyca, M. E., Nair, S. C., Jilma, B., Priya, S., Male, C., Reitter, S. E., Knöbl, P., Gilbert, J. C., Schaub, R. G., Dockal, M., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04790.x · Cited by 57
Mabry, R., Gilbertson, D. G., Frank, A., Vu, T., Ardourel, D., Ostrander, C. D., Stevens, B. L., Julien, S. H., Franke, S., Meengs, B., et al. (2010) · mAbs · doi:10.4161/mabs.2.1.10498 · Cited by 56
Cancer immunotherapy via nucleic acid aptamers
Khedri, M., Rafatpanah, H., Abnous, K., Ramezani, P., & Ramezani, M. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.10.013 · Cited by 54
Physicochemical Stability of NOX-E36, a 40mer L-RNA (Spiegelmer) for Therapeutic Applications
Maasch, C., Buchner, K., Eulberg, D., Vonhoff, S., & Klussmann, S. (2008) · Nucleic Acids Symposium Series · doi:10.1093/nass/nrn031 · Cited by 50
Avci‐Adali, M., Metzger, M., Perle, N., Ziemer, G., & Wendel, H. P. (2010) · Oligonucleotides · doi:10.1089/oli.2010.0253 · Cited by 46
The Complement Component 5 Gene and Age-Related Macular Degeneration
Baas, D. C., Ho, L., Ennis, S., Merriam, J. E., Tanck, M. W. T., Uitterlinden, A. G., de Jong, P. T. V. M., Cree, A. J., Griffiths, H., Rivadeneira, F., et al. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.08.032 · Cited by 44
Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers
Hernandez, L. I., Flenker, K. S., Hernández, F. J., Klingelhutz, A. J., McNamara, J. O., & Giangrande, P. H. (2013) · Pharmaceuticals · doi:10.3390/ph6030295 · Cited by 40
Smooth Muscle Cell–targeted RNA Aptamer Inhibits Neointimal Formation
Thiel, W. H., Esposito, C. L., Dickey, D. D., Dassie, J. P., Long, M. E., Adam, J., Streeter, J., Schickling, B., Takapoo, M., Flenker, K. S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.235 · Cited by 36
NOX-A12: mobilizing CLL away from home
Marasca, R., & Maffei, R. (2014) · Blood · doi:10.1182/blood-2013-12-542480 · Cited by 34
Sadiq, M. A., Hanout, M., Sarwar, S., Hassan, M., Diana, V., Nguyen, Q. D., & Sepah, Y. J. (2015) · Saudi Journal of Ophthalmology · doi:10.1016/j.sjopt.2015.05.005 · Cited by 34
Vitreous Injections of Pegaptanib Sodium Triggering Allergic Reactions
Steffensmeier, A., Azar, A., Fuller, J. J., Muller, B. A., & Russell, S. R. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.10.007 · Cited by 31
Kawaguchi, T., ASAKAWA, H., TASHIRO, Y., Juni, K., & Sueishi, T. (1995) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.18.474 · Cited by 30
Povsic, T. J., Vavalle, J. P., Alexander, J. H., Aberle, L. H., Zelenkofske, S. L., Becker, R. C., Buller, C. E. H., Cohen, M. G., Cornel, J. H., Kasprzak, J. D., et al. (2014) · EuroIntervention · doi:10.4244/eijy14m06_01 · Cited by 30
Boyer, D. S. (2009) · Investigative Ophthalmology & Visual Science · Cited by 22
Boyer, D. S., Goldbaum, M., LEYS, A. M., Starita, C., & for the V.I.S.I.O.N. Study Group (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304075 · Cited by 22
Factor IXa as a target for anticoagulation in thrombotic disorders and conditions.
Smiley, D. A., & Becker, R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.028 · Cited by 18
Boyer, D. S. (2013) · Investigative Ophthalmology & Visual Science · Cited by 14
A dual function TAR Decoy serves as an anti-HIV siRNA delivery vehicle
Unwalla, H. J., & Rossi, J. J. (2010) · Virology Journal · doi:10.1186/1743-422x-7-33 · Cited by 14
Self-citationAn anticoagulant too good to be true for revascularisation
Verheugt, F. W. A. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00727-8 · Cited by 9
Cited by
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Self-citationDrug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Targeting STAT3 in Cancer Immunotherapy
Zou, S., Tong, Q., Liu, B., Huang, W., Tian, Y., & Fu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01258-7 · Cited by 1,050
Undulating changes in human plasma proteome profiles across the lifespan
Lehallier, B., Gate, D., Schaum, N., Nanasi, T., Lee, S. E., Yousef, H., Moran Losada, P., Berdnik, D., Keller, A., Verghese, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0673-2 · Cited by 981
Emerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 971
Metadata
- Authors
- Zhou, J., & Rossi, J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2016-11-03
- Volume
- 16
- Issue
- 3
- Pages
- 181-202
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2547782348
- Cited by
- 2,221
- References
- 191
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.